Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners
04 Novembro 2021 - 10:00AM
Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today
announced that Paula Brown Stafford, President and Chief Executive
Officer of Novan, recently participated in a fireside chat hosted
by Jonathan Aschoff, Ph.D., Managing Director, Senior Research
Analyst at ROTH Capital Partners.
As part of the fireside chat, Mrs. Stafford
discussed the progress of Novan’s priority development pipeline
including its recently completed B-SIMPLE4 study of SB206 for the
treatment of molluscum and preparation for commercial launch of
SB206, if approved by the U.S. Food and Drug Administration (FDA).
Additionally, Mrs. Stafford outlines how the Company is currently
executing on its plan to submit three potential New Drug
Application (NDA) filings in three years, with the first submission
targeted for Q3 2022 for lead program SB206 in molluscum
contagiosum.
A video webcast of the fireside chat is
accessible on the Events page in the Investors section of the
Company’s website (novan.com) and will be available for 90
days.
About Novan
Novan, Inc. is a pre-commercial nitric
oxide-based pharmaceutical company focused on dermatology and
anti-infective therapies. We leverage our core synergies of
science, capital, resources and patient needs to create value by
bringing new nitric oxide-based medicines to market. Our goal is to
create the world’s leader in nitric oxide-based science,
technology, and clinical translation in support of delivering safe
and efficacious therapies using our proprietary nitric oxide-based
technology platform, NITRICIL™ to generate macromolecular New
Chemical Entities (NCEs) to treat multiple indications.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe,” “expect,” “target,”
“anticipate,” “may,” “plan,” “potential,” “will,” and similar
expressions, and are based on the Company’s current beliefs and
expectations. These forward-looking statements include, but are not
limited to, statements related to the potential therapeutic value
of the Company’s NITRICIL™ platform technology, the Company’s
pharmaceutical development of nitric oxide-releasing product
candidates, including SB206, and the potential timing of FDA
submission(s). Forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from the Company’s expectations, including, but
not limited to, risks related to the regulatory approval process,
which is lengthy, time-consuming and inherently unpredictable,
including the risk that the FDA will not agree with the Company’s
approach to a potential NDA submission, that the Company’s product
candidates may not be approved or that additional studies may be
required for approval or other delays may occur, that the Company
may not have sufficient quantities of drug substance and/or drug
product to support regulatory submissions and that the Company may
not obtain funding sufficient to complete the regulatory or
development process; the Company’s limited experience as a company
in obtaining regulatory approvals and commercializing
pharmaceutical products; changes in the size and nature of the
market for the Company’s product candidates, including potential
competition; any operational or other disruptions as a result of
the COVID-19 pandemic; the Company’s ability to obtain additional
funding or enter into strategic or other business relationships
necessary or useful for the further development or
commercialization of the Company’s product candidates; risks
related to the manufacture of raw materials, including the
Company’s active pharmaceutical ingredient and drug product
components utilized in clinical trial materials, such as supply
chain disruptions or delays, failure to transfer technology and
processes to third parties effectively or failure of those third
parties (or the Company in connection with the upfit of the
Company’s new facility) to obtain approval of and maintain
compliance with the FDA or comparable regulatory authorities; the
Company’s reliance on arrangements with third parties to support
its operations and its development and commercialization efforts
and the risk that such parties will not successfully carry out
their contractual duties or meet expected deadlines; and other
risks and uncertainties described in the Company’s annual report
filed with the Securities and Exchange Commission on Form 10-K for
the twelve months ended December 31, 2020, and in the Company’s
subsequent filings with the Securities and Exchange Commission.
Such forward-looking statements speak only as of the date of this
press release, and Novan disclaims any intent or obligation to
update these forward-looking statements to reflect events or
circumstances after the date of such statements, except as may be
required by law.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas JTC Team,
LLC833-475-8247NOVN@jtcir.com
Novan (NASDAQ:NOVN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novan (NASDAQ:NOVN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024